Value of benralizumab in the treatment of severe eosinophilic asthma

doi:10.3877/cma.j.issn.1674-0785.2018.05.010

Abstract

Abstract:

Bronchial asthma is a common chronic airway disease. The symptoms of some patients treated according to the guidelines are still not satisfactorily controlled, especially in eosinophilic asthma patients who are symptomatic despite treatment with inhaled corticosteroids and a long-acting beta2-agonist. Benralizumab is a humanized interleukin-5 receptor antibody. In this paper, we will review the fundamental characteristics of benralizumab as well as its clinical evaluation, safety, and application prospect in the treatment of eosinophilic asthma.

Key words: Benralizumab, Asthma, Eosinophils, Interleukin-5

Wenwen Li, ke Cao, Qiannan Zhao, Yanmeng Kang, Caiqing Zhang. Value of benralizumab in the treatment of severe eosinophilic asthma[J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(05): 306-309.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2018.05.010

https://zhlcyszz.cma-cmc.com.cn/EN/Y2018/V12/I05/306

References 23

1	中华医学会呼吸病学分会哮喘学组，中国哮喘联盟. 重症哮喘诊断与处理中国专家共识[J].中华结核和呼吸杂志, 2017, 40(11):813-829.
2	Shrimanker R. Interleukin-5 inhibitors for severe asthma: rationale and future outlook [J]. BioDrugs, 2017, 31(2):93-103.
3	Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [J]. Eur Respir J, 2014, 43(2):343-373.
4	Haasler I.Biologicals in the treatment of bronchial asthma [J]. Pneumologie, 2017, 71(10):684-698.
5	Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity [J]. Hum antibodies, 2009, 18(1-2):17-27.
6	Ghazi A, Trikha A, Calhoun WJ. Benralizumab-a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma [J]. Expert opini Biol Ther, 2012, 12(1):113-118.
7	Tavernier J, Devos R, Cornelis S, et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF [J]. Cell, 1991, 66(6):1175-1184.
8	Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity [J]. Hum Antibodies, 2009, 18(1-2):17-27.
9	Busse WW, Katial R, Gossage D, et al.Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phaseⅠ study of subjects with mild asthma [J]. J Allergy Clin Immunol, 2010, 125(6):1237-1244.
10	Saco TV, Pepper AN, Lockey RF. Benralizumab for the treatment of asthma [J]. Expert Rev Clin Immunol, 2017, 13(5):405-413.
11	Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity [J]. J Biol Chem, 2002, 277(30):26733-26740.
12	Matera MG, Calzetta L, Rinaldi B, et al. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma [J]. Expert opin Drug Metab Toxicol, 2017, 13(9):1007-1013.
13	Kaufman MB. Pharmaceutical approval update [J]. P T, 2018, 43(1):22-60.
14	Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function [J]. J Allergy Clin Immunol, 2010, 125(6):1344-1353.
15	Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia [J]. J Allergy Clin Immunol, 2013, 132(5):1086-1096.
16	Khorasanizadeh M, Eskian M, Rezaei N. Reductions in eosinophil biomarkers by benralizumab in patients with asthma [J]. Acta Med Iran, 2017, 55(5):352-353.
17	Nowak RM, Parker JM, Silverman RA, et al.A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma [J]. Am J Emerg Med, 2015, 33(1):14-20.
18	Bleecker ER, FitzGerald JM, Chanez P, et al.Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β₂-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J]. Lancet, 2016, 388(10056):2115-2127.
19	FitzGerald JM, Bleecker ER, Nair P, et al.Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial [J]. Lancet, 2016, 388(10056):2128-2141.
20	Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma [J]. N Engl J Med, 2017, 376(25):2448-2458.
21	Antoniu SA. Benralizumab as a potential treatment of asthma [J]. Expert Opin Biol Ther, 2017, 17(7):895-900.
22	Tian BP, Zhang GS, Lou J, et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials [J]. J Asthma, Epub 2017 Dec 6:1-10.
23	Matera MG, Calzetta L,Rinaldi B, et al.Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma [J]. Expert Opin Drug Metab Toxicol, 2017, 13(9):1007-1013.

[1]	Haoyuan Yang, Jie Gong, Qingwei Zou, Hang Ruan. Current research status on adverse pregnancy outcomes of maternal and infant in pregnant women with asthma [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 522-529.
[2]	Lili Lou, Hanmin Liu. Current research status of susceptibility genes and epigenetics on childhood asthma [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(03): 249-255.
[3]	Jinli Yan, Dapeng Chen. Research progress on probiotics in clinical application of neonatal respiratory diseases [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(05): 517-522.
[4]	Tengteng Zhang, Jimei Bian, Zhongping Zhang, Haiyan Wang, Xiaojuan Liu, Lina Zhen. Clinical application of bronchial provocation tests in childhood asthma management [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(02): 221-225.
[5]	Hansheng Wang, Xiao Chen, Hui You, Liu Yan, Tao Ren, Meifang Wang. Clinical analysis of exudative pleural effusion caused by paragonimus infection in 6 patients [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 348-353.
[6]	Lingfang Tan, Kebing Zhou. Identification of biomarkers associated with diagnosis of bronchial asthma based on integrated bioinformatics analysis [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(03): 329-334.
[7]	Chao Zhang, Xiaozhe Yue. Association of eosinophils, total IgE with severity and lung function in children with asthma [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(02): 183-186.
[8]	Jianghua Li, Li Li, Yubo Wang, Hengyi Chen, Yong He. Predictive value of exhaled nitric oxide and blood eosinophils on the degree of airway hyperresponsiveness in asthma patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(01): 24-30.
[9]	Mengqing Shen, Ting Wu, Fei Wang. Effects of budesonide combined with specific immunotherapy on the levels of 1, 25-dihydroxyvitamin D3, IL-6 and IL-10 in children with bronchial asthma [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(01): 43-47.
[10]	Li Wang, Xiaojun Wang. TH17 cells balance and mechanism in the immune microenvironment on the pathogenesis of allergic asthma [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(05): 648-652.
[11]	Jingen Xia, Shiyu Hu. Application scenario of extracorporeal carbon dioxide removal technology in Intensive Care Unit [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2023, 09(01): 40-45.
[12]	Rongju Wu, Pingchao Xiang. Correlation between frequent exacerbation phenotype of chronic obstructive pulmonary disease and inflammatory markers [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 939-947.
[13]	Xiaoning Zhang, Jianguang Qi. Progress in application of shared decision-making in children with bronchial asthma [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(07): 542-546.
[14]	Yawen Gao, Fang Xu, Luning Jiang. Research progress in diagnosis of bronchial asthma and treatment with cysteinyl leukotriene receptor antagonist [J]. Chinese Journal of Diagnostics(Electronic Edition), 2021, 09(01): 67-70.
[15]	Alimu·Maimaiti, Faming Tao, Zhaoyang Wu, Zulipeiya·Aibaidoula, Kelimu·Abudureyimu. Analysis of the characteristics of swallowing related cough and acid reflux in asthma patients [J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2021, 08(02): 81-84.

Please choose a citation manager

Content to export